Published in J Nutr on June 01, 2007
Non-physiological amino acid (NPAA) therapy targeting brain phenylalanine reduction: pilot studies in PAHENU2 mice. J Inherit Metab Dis (2012) 0.98
Altered brain protein expression profiles are associated with molecular neurological dysfunction in the PKU mouse model. J Neurochem (2014) 0.84
Development of the US English version of the phenylketonuria - quality of life (PKU-QOL) questionnaire. Health Qual Life Outcomes (2017) 0.75
The Predictive Value of Genetic Analyses in the Diagnosis of Tetrahydrobiopterin (BH4)-Responsiveness in Chinese Phenylalanine Hydroxylase Deficiency Patients. Sci Rep (2017) 0.75
Once-daily valacyclovir to reduce the risk of transmission of genital herpes. N Engl J Med (2004) 5.04
Recommendations for the management of herpes zoster. Clin Infect Dis (2007) 4.33
A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N Engl J Med (2003) 3.67
Varicella-zoster virus in the saliva of patients with herpes zoster. J Infect Dis (2008) 3.52
Multiple phenotypes in phosphoglucomutase 1 deficiency. N Engl J Med (2014) 2.62
Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial. J Am Acad Dermatol (2007) 2.26
Tropical dermatology: fungal tropical diseases. J Am Acad Dermatol (2005) 2.08
A randomized, placebo-controlled trial of oxycodone and of gabapentin for acute pain in herpes zoster. Pain (2009) 2.01
Update on Kaposi's sarcoma and other HHV8 associated diseases. Part 1: epidemiology, environmental predispositions, clinical manifestations, and therapy. Lancet Infect Dis (2002) 1.80
Tropical dermatology: bacterial tropical diseases. J Am Acad Dermatol (2006) 1.69
Genetic polymorphisms of methylenetetrahydrofolate reductase (MTHFR) and methionine synthase reductase (MTRR) in ethnic populations in Texas; a report of a novel MTHFR polymorphic site, G1793A. Am J Med Genet (2002) 1.67
Defective N-acetylaspartate catabolism reduces brain acetate levels and myelin lipid synthesis in Canavan's disease. Proc Natl Acad Sci U S A (2005) 1.60
Dual mechanism of action of ingenol mebutate gel for topical treatment of actinic keratoses: rapid lesion necrosis followed by lesion-specific immune response. J Am Acad Dermatol (2011) 1.51
Inhibition of smoothened signaling prevents ultraviolet B-induced basal cell carcinomas through regulation of Fas expression and apoptosis. Cancer Res (2004) 1.50
Sex differences in the transmission, prevention, and disease manifestations of sexually transmitted diseases. Arch Dermatol (2006) 1.49
Generalized verrucosis: a review of the associated diseases, evaluation, and treatments. J Am Acad Dermatol (2011) 1.46
Association of proinflammatory cytokine gene polymorphisms with susceptibility to otitis media. Pediatrics (2006) 1.42
A review of licensed viral vaccines, some of their safety concerns, and the advances in the development of investigational viral vaccines. J Infect (2004) 1.42
Tropical dermatology: viral tropical diseases. J Am Acad Dermatol (2003) 1.40
MD/PhDs are more likely than MDs to choose a career in academic dermatology. Dermatol Online J (2008) 1.39
An HIV-Positive Male with a Herald Plaque. Clin Infect Dis (2011) 1.38
Topical resiquimod 0.01% gel decreases herpes simplex virus type 2 genital shedding: a randomized, controlled trial. J Infect Dis (2007) 1.37
Nested PCR with the PGMY09/11 and GP5(+)/6(+) primer sets improves detection of HPV DNA in cervical samples. J Virol Methods (2004) 1.37
The Maternal Phenylketonuria International Study: 1984-2002. Pediatrics (2003) 1.37
Tropical dermatology: Venomous arthropods and human skin: Part I. Insecta. J Am Acad Dermatol (2012) 1.35
Activation of the hedgehog pathway in a subset of lung cancers. Cancer Lett (2006) 1.34
Update on Kaposi's sarcoma and other HHV8 associated diseases. Part 2: pathogenesis, Castleman's disease, and pleural effusion lymphoma. Lancet Infect Dis (2002) 1.31
Correction of kinetic and stability defects by tetrahydrobiopterin in phenylketonuria patients with certain phenylalanine hydroxylase mutations. Proc Natl Acad Sci U S A (2004) 1.28
Long-term follow-up study of ingenol mebutate gel for the treatment of actinic keratoses. JAMA Dermatol (2013) 1.25
Family history as a risk factor for herpes zoster: a case-control study. Arch Dermatol (2008) 1.24
The expanding spectrum of eschar-associated rickettsioses in the United States. Arch Dermatol (2010) 1.24
Role for plasmacytoid dendritic cells in the immune control of recurrent human herpes simplex virus infection. J Virol (2008) 1.24
Cutaneous metastasis to the chest wall from prostate cancer. Int J Dermatol (2006) 1.20
A single intravenous rAAV injection as late as P20 achieves efficacious and sustained CNS Gene therapy in Canavan mice. Mol Ther (2013) 1.19
Cutaneous castleman's disease responds to anti interleukin-6 treatment. Mol Cancer Ther (2007) 1.17
Persistence of varicella zoster virus DNA in saliva after herpes zoster. J Infect Dis (2011) 1.17
Safety and immunogenicity of glycoprotein D-adjuvant genital herpes vaccine. Clin Infect Dis (2005) 1.16
Dermatology residency program characteristics that correlate with graduates selecting an academic dermatology career. Arch Dermatol (2006) 1.14
Beyond a decade of 5% imiquimod topical therapy. J Drugs Dermatol (2009) 1.12
A randomized controlled trial of a replication defective (gH deletion) herpes simplex virus vaccine for the treatment of recurrent genital herpes among immunocompetent subjects. Vaccine (2005) 1.09
Herpes simplex viruses 1 and 2. Dermatol Clin (2002) 1.07
Tropical dermatology: marine and aquatic dermatology. J Am Acad Dermatol (2009) 1.07
Treatment of a patient with epidermodysplasia verruciformis carrying a novel EVER2 mutation with imiquimod. J Am Acad Dermatol (2007) 1.05
Safety, tolerability, and immunogenicity of zoster vaccine in subjects with a history of herpes zoster. Vaccine (2010) 1.04
Detection of human papillomavirus in cutaneous clear cell squamous cell carcinoma in situ: viral-associated oncogenesis may contribute to the development of this pathologic variant of skin cancer. J Cutan Pathol (2008) 1.04
Long-term administration of valacyclovir reduces the number of Epstein-Barr virus (EBV)-infected B cells but not the number of EBV DNA copies per B cell in healthy volunteers. J Virol (2009) 1.03
Association between cytokine gene polymorphisms and risk for upper respiratory tract infection and acute otitis media. Clin Infect Dis (2009) 1.02
Error-free replicative bypass of thymine glycol by the combined action of DNA polymerases kappa and zeta in human cells. Proc Natl Acad Sci U S A (2010) 1.02
Specific HIV gp120-cleaving antibodies induced by covalently reactive analog of gp120. J Biol Chem (2003) 1.01
Once, twice, or three times daily famciclovir compared with aciclovir for the oral treatment of herpes zoster in immunocompetent adults: a randomized, multicenter, double-blind clinical trial. J Clin Virol (2004) 1.01
Ranking the dermatology programs based on measurements of academic achievement. Dermatol Online J (2007) 0.98
Herpesvirus prevalence and viral load in healthy blood donors by quantitative real-time polymerase chain reaction. Transfusion (2008) 0.98
Actinic keratoses: sequelae and treatments. Recommendations from a consensus panel. J Fam Pract (2006) 0.98
Subcutaneous fungal infections. Dermatol Ther (2004) 0.98
Managing herpes zoster in immunocompromised patients. Herpes (2007) 0.96
Human papillomavirus: a review. Dermatol Clin (2002) 0.96
Varicella zoster virus DNA at inoculation sites and in saliva after Zostavax immunization. J Infect Dis (2011) 0.96
Biological and clinical basis for molecular studies of interferons. Methods Mol Med (2005) 0.95
Therapy of nontuberculous mycobacterial infections. Dermatol Ther (2004) 0.93
Differentiation-dependent expression of signal transducers and activators of transcription (STATs) might modify responses to growth factors in the cancers of the head and neck. Cancer Lett (2003) 0.93
Adeno-associated virus-mediated aspartoacylase gene transfer to the brain of knockout mouse for canavan disease. Mol Ther (2003) 0.92
Viral and nonviral uses of imiquimod: a review. J Cutan Med Surg (2005) 0.91
An update on the clinical management of cutaneous molluscum contagiosum. Skin Therapy Lett (2014) 0.90
Tropical dermatology: Venomous arthropods and human skin: Part II. Diplopoda, Chilopoda, and Arachnida. J Am Acad Dermatol (2012) 0.90
Rapidly enlarging growth of the proximal nail fold. Dermatol Surg (2003) 0.90
Selected sexually transmitted diseases and their relationship to HIV. Clin Dermatol (2004) 0.90
Molecular diagnosis of infectious diseases in dermatology. J Am Acad Dermatol (2005) 0.90
Acute otitis media severity: association with cytokine gene polymorphisms and other risk factors. Int J Pediatr Otorhinolaryngol (2011) 0.89
Trends in enzyme therapy for phenylketonuria. Mol Ther (2004) 0.89
Antibiotic overuse and resistance in dermatology. Dermatol Ther (2012) 0.89
Novel homozygous frameshift mutation of EVER1 gene in an epidermodysplasia verruciformis patient. J Invest Dermatol (2006) 0.89
Biopterin responsive phenylalanine hydroxylase deficiency. Genet Med (2004) 0.88
Regulation of adrenal glucocorticoid synthesis by interleukin-10: a preponderance of IL-10 receptor in the adrenal zona fasciculata. Brain Behav Immun (2005) 0.88
Safety, tolerability, and immunogenicity after 1 and 2 doses of zoster vaccine in healthy adults ≥60 years of age. Vaccine (2011) 0.88
Seborrheic Keratosis-like lesions in patients with epidermodysplasia verruciformis. J Dermatol (2003) 0.87
Aspartoacylase deficiency affects early postnatal development of oligodendrocytes and myelination. Neurobiol Dis (2010) 0.87
Lack of aspartoacylase activity disrupts survival and differentiation of neural progenitors and oligodendrocytes in a mouse model of Canavan disease. J Neurosci Res (2009) 0.87
Deletions in chromosome 6p22.3-p24.3, including ATXN1, are associated with developmental delay and autism spectrum disorders. Mol Cytogenet (2012) 0.87
Resiquimod: a new immune response modifier with potential as a vaccine adjuvant for Th1 immune responses. Antiviral Res (2004) 0.87
Demographic, behavioral, and knowledge factors associated with herpes simplex virus type 2 infection among men whose current female partner has genital herpes. Sex Transm Dis (2005) 0.86
Polymorphisms for chemical metabolizing genes and risk for cervical neoplasia. Environ Mol Mutagen (2003) 0.86
Viremia in acute herpes zoster. J Infect Dis (2009) 0.86
Ceftaroline in complicated skin and skin-structure infections. Infect Drug Resist (2012) 0.86
Neuronal localization of the mitochondrial protein NIPSNAP1 in rat nervous system. Eur J Neurosci (2010) 0.86
Tetrahydrobiopterin and maternal PKU. Mol Genet Metab (2005) 0.86
Upregulation of aspartoacylase activity in the duodenum of obesity induced diabetes mouse: implications on diabetic neuropathy. Biochem Biophys Res Commun (2006) 0.85
Human papillomaviruses vaccine: a dermatologic perspective. Indian J Dermatol Venereol Leprol (2010) 0.85
Retapamulin: an antibacterial with a novel mode of action in an age of emerging resistance to Staphylococcus aureus. J Drugs Dermatol (2010) 0.85
Varicella zoster: an update on current treatment options and future perspectives. Expert Opin Pharmacother (2013) 0.85
The cutaneous manifestations of HIV infection. Dermatol Clin (2002) 0.85
Physiological role of N-acetylaspartate: contribution to myelinogenesis. Adv Exp Med Biol (2006) 0.85
Pregnancy experiences in the woman with mild hyperphenylalaninemia. Pediatrics (2003) 0.85
Interleukin-10 induces transcription of the early promoter of human papillomavirus type 16 (HPV16) through the 5'-segment of the upstream regulatory region (URR). Antiviral Res (2002) 0.84
Suppression of growth by all-trans retinoic acid requires prolonged induction of interferon regulatory factor 1 in cervical squamous carcinoma (SiHa) cells. Clin Diagn Lab Immunol (2002) 0.84
Therapy of cutaneous human Papillomavirus infections. Dermatol Ther (2004) 0.84
Clinical, histopathological and virological findings in patients with focal epithelial hyperplasia from Colombia. Int J Dermatol (2005) 0.84
Family history and herpes zoster risk in the era of shingles vaccination. J Clin Virol (2011) 0.83